An observational study of vascular endothelial growth factor inhibitors as second-line treatment for metastatic colorectal cancer treated with bevacizumab plus FOLFIRI beyond progression: the association with RAS mutation and tumor sidedness

BACKGROUND: The BRiTE and ARIES studies suggested that the continued use of bevacizumab beyond progression (BBP) was beneficial. This study investigated the efficacy and safety of the vascular endothelial growth factor inhibitors (VEGFis) bevacizumab and aflibercept as second-line treatments for pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Hsiang-Lin, Huang, Ching-Wen, Ma, Cheng-Jen, Su, Wei-Chih, Chang, Tsung-Kun, Chen, Po-Jung, Yeh, Yung-Sung, Wang, Jaw-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798720/
https://www.ncbi.nlm.nih.gov/pubmed/35116988
http://dx.doi.org/10.21037/tcr.2019.09.59

Ejemplares similares

Ejemplares similares